NVSNovartis PharmaceuticalsRunning, no new patients
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Differentiated Thyroid Cancer (DTC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 153 (final count)
- Started
- Nov 15, 2021
- Main results expected
- Jan 22, 2025
- Fully finished
- May 25, 2027
- Results posted
- May 22, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04940052 · record last updated 2026-09-21 · checked 2026-11-09 15:47 UTC